Uterine serous cancer constitutes up to 10% of all endometrial tumors, and represents the most biologically aggressive variant of type II EC. This article will describe the most salient molecular ...

Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

Q-901 is under clinical development by Qurient and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

Common early uterine cancer symptoms include atypical vaginal bleeding (including after menopause), unusual vaginal discharge, and pelvic pain. The condition is most common in females above 50 ...

Our center emphasizes personalized care for people with uterine sarcomas, low-grade serous ovarian carcinoma, uterine serous carcinoma, clear cell and mucinous tumors of the ovary, germ cell and sex ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

VET3-T12 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I drugs for Uterine Cancer have an 80% phase transition ...

Barclays PLC increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% in the 3rd quarter ...